1、 LI D,ZHAO X,PI X,et al.Systemic immune-inflammation index and the survival of hepatocellular carcinoma patients after transarterial chemoembolization:A meta-analysis[J].Clin Exp Med,2022,23(6):2105-2114. LI D,ZHAO X,PI X,et al.Systemic immune-inflammation index and the survival of hepatocellular carcinoma patients after transarterial chemoembolization:A meta-analysis[J].Clin Exp Med,2022,23(6):2105-2114.
2、 HONG Y M,YOON K T,CHO M.Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma[J].BMC Cancer,2021,21(1):569. HONG Y M,YOON K T,CHO M.Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma[J].BMC Cancer,2021,21(1):569.
3、 HU B,YANG X R,XU Y,et al.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J].Clin Cancer Res,2014,20(23):6212-6222. HU B,YANG X R,XU Y,et al.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J].Clin Cancer Res,2014,20(23):6212-6222.
4、 章金丽,张奇,朱红娟,等.系统炎症指数变化率在预测肝细胞肝癌复发中的意义[J].肿瘤学杂志,2017,23(8):667-671. 章金丽,张奇,朱红娟,等.系统炎症指数变化率在预测肝细胞肝癌复发中的意义[J].肿瘤学杂志,2017,23(8):667-671.
5、 MARGETTS J,OGLE L F,CHAN S L,et al.Neutrophils:driving progression and poor prognosis in hepatocellular carcinoma?[J].Br J Cancer,2018,118(2):248-257. MARGETTS J,OGLE L F,CHAN S L,et al.Neutrophils:driving progression and poor prognosis in hepatocellular carcinoma?[J].Br J Cancer,2018,118(2):248-257.
6、 PANG Q,ZHOU L,QU K,et al.Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma:A retrospective observational study[J].Eur J Gastroenterolo Hepatol,2018,30(1):60-70. PANG Q,ZHOU L,QU K,et al.Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma:A retrospective observational study[J].Eur J Gastroenterolo Hepatol,2018,30(1):60-70.
7、 CASADEI GARDINI A,FOSCHI F G,CONTI F,et al.Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals[J].Dig Liver Dis,2019,51(5):681-688. CASADEI GARDINI A,FOSCHI F G,CONTI F,et al.Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals[J].Dig Liver Dis,2019,51(5):681-688.
8、 FU H,ZHENG J,CAI J,et al.Systemic immune-inflammation index(SII)is useful to predict survival outcomes in patients after liver transplantation for hepatocellular carcinoma within Hangzhou criteria[J].Cellr Physiolo Biochem,2018,47(1):293-301. FU H,ZHENG J,CAI J,et al.Systemic immune-inflammation index(SII)is useful to predict survival outcomes in patients after liver transplantation for hepatocellular carcinoma within Hangzhou criteria[J].Cellr Physiolo Biochem,2018,47(1):293-301.
9、 WANG C,HE W,YUAN Y,et al.Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy[J].Liver Int,2020,40(1):229-239. WANG C,HE W,YUAN Y,et al.Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy[J].Liver Int,2020,40(1):229-239.
10、 张喜文,高裕,徐慧,等.术前全身免疫炎症指数评价上尿路上皮癌患者术后膀胱复发风险的价值[J].现代泌尿外科杂志,2022,27(1):30-34. 张喜文,高裕,徐慧,等.术前全身免疫炎症指数评价上尿路上皮癌患者术后膀胱复发风险的价值[J].现代泌尿外科杂志,2022,27(1):30-34.
11、 CHEN J H,ZHAI E T,YUAN Y J,et al.Systemic immune-inflammation index for predicting prognosis of colorectal cancer[J].World J Gastroenterol,2017,23(34):6261-6272. CHEN J H,ZHAI E T,YUAN Y J,et al.Systemic immune-inflammation index for predicting prognosis of colorectal cancer[J].World J Gastroenterol,2017,23(34):6261-6272.
12、 《原发性肝癌诊疗规范(2019年版)》编写专家委员会.原发性肝癌诊疗规范(2019年版)[J].中国临床医学,2020,27(1):140-156. 《原发性肝癌诊疗规范(2019年版)》编写专家委员会.原发性肝癌诊疗规范(2019年版)[J].中国临床医学,2020,27(1):140-156.
13、 李婵,吴远鹏,吴吉进,等.SII预测恶性实体肿瘤预后的研究进展[J].实用医院临床杂志,2018,15(3):252-254. 李婵,吴远鹏,吴吉进,等.SII预测恶性实体肿瘤预后的研究进展[J].实用医院临床杂志,2018,15(3):252-254.
14、 王凤梅,李超,贾文玲,等.炎性微环境与肝癌发生间关系的研究进展[J].肿瘤,2015,35(11):1282-1286. 王凤梅,李超,贾文玲,等.炎性微环境与肝癌发生间关系的研究进展[J].肿瘤,2015,35(11):1282-1286.
15、 陈姚,张万广,陈孝平,等.一项构建BCLC 0~A期肝细胞癌病人R0切除术后肝内早期复发风险预测列线图的回顾性研究[J].腹部外科,2021,34(6):447-452. 陈姚,张万广,陈孝平,等.一项构建BCLC 0~A期肝细胞癌病人R0切除术后肝内早期复发风险预测列线图的回顾性研究[J].腹部外科,2021,34(6):447-452.
16、 陈凯,杨洪吉,邓小凡,等.肝癌根治性切除术后早期复发危险因素分析及预测模型构建[J].中华肿瘤防治杂志,2018,25(5):344-348. 陈凯,杨洪吉,邓小凡,等.肝癌根治性切除术后早期复发危险因素分析及预测模型构建[J].中华肿瘤防治杂志,2018,25(5):344-348.
17、 胡继科,李雪梅,张凡,等.肝癌术后复发危险因素影响研究进展[J].中华肝胆外科杂志,2018,24(9):644-648. 胡继科,李雪梅,张凡,等.肝癌术后复发危险因素影响研究进展[J].中华肝胆外科杂志,2018,24(9):644-648.
18、 耿小平. 原发性肝癌外科治疗的选择[J].肝胆外科杂志,2014,22(4):248-249. 耿小平. 原发性肝癌外科治疗的选择[J].肝胆外科杂志,2014,22(4):248-249.
19、 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版)[J].中国实用外科杂志,2022,42(3):241-273. 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版)[J].中国实用外科杂志,2022,42(3):241-273.
20、 CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132. CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
21、 SIEGEL R L,MILLER K D,FUCHS H E,et al.Cancer Statistics,2021[J].CA Cancer J Clin,2021,71(1):7-33. SIEGEL R L,MILLER K D,FUCHS H E,et al.Cancer Statistics,2021[J].CA Cancer J Clin,2021,71(1):7-33.
